+ Watch PDII
on My Watchlist
A sales and marketing services company, which serves the biopharmaceutical and life sciences industries.
EPS Surprise: +EPS Est Rev: UP5 Yr Est EPS Growth: 20%DFA & HeartlandGreat value, trading at cash value (floor), equals great upside with limited downside exposure.
A Value Proposition
Trading below book value, new management. Their price was beaten down for loss of a large contract, but they've since picked up another. Not profitable at the moment, but with the company trading below book value your risks are pretty low. With the new sales director this stock can only get better.
Provides outsourced sales & marketing force capability for Pharma companies, that can either replace or augment an in-house sales force. Currently beaten down by the loss of 3 major accounts as of Dec 06 (GSK, SNY, Astra-Zeneca) accounting for $126M (56%) of revenues. Forward EPS -1.46 for '07 and negative again for '08. President of Sales just "resigned" in 4/07, and a somewhat nebulous "long-term strategic plan" will be implemented in 2007. Major selling point on this stock is that as of 4/07 it's trading below book value (P/B 0.88) giving potentially a margin of safety. But who knows, turnarounds can work. So I'll give it a short-term thumbs down, but may offer a good value opportunity for a risk-tolerant LT buy-and-hold portfolio.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions